TP53 in urologic tumors

Analytical and Quantitative Cytology and Histology

Volumn 25, Issue 3, 2003, Pages 123-130

  Algaba, Ferran ^a   Trias, Isabel ^c   Santinelli, Alfredo ^b   Montironi, Rodolfo ^b  

^a UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^b UNIVERSITÀ POLITECNICA DELLE MARCHE   (Italy)

^c Universitat Autonoma de Barcelona ^*

Author keywords

Bladder cancer; p53 protein; TP53 genes; Urologic cancer

Indexed keywords

PROTEIN P53;

ARTICLE; BLADDER CANCER; CANCER DIAGNOSIS; CANCER GENETICS; CELL CYCLE; CORRELATION ANALYSIS; CYSTECTOMY; DIAGNOSTIC VALUE; GENE; GENE FUNCTION; GENE INACTIVATION; GENE MUTATION; GENE OVEREXPRESSION; GERM CELL TUMOR; HALF LIFE TIME; HUMAN; IMMUNOHISTOCHEMISTRY; KIDNEY CARCINOMA; MALE; MOLECULAR RECOGNITION; PENIS CARCINOMA; PRIORITY JOURNAL; PROSTATE CARCINOMA; PROTEIN DEGRADATION; SUPERFICIAL CANCER; TP53 GENE; URINARY TRACT CANCER;

ADENOCARCINOMA; GENES, P53; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; NEOPLASM PROTEINS; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53; URINARY BLADDER NEOPLASMS;

EID: 0038472052     PISSN: 08846812     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (56)

1. Choisy-Rossi C, Reisdorf P, Yonish-Rouach E: The p53 tumor suppressor gene: Structure, function and mechanism of action. Results Probl Cell Differ 1999;23:145-172
2. Cho Y, Gorina S, Jeffrey PD, Pavletich NP: Crystal structure of a p53 tumor suppressor-DNA complex: Understanding tumorigenic mutations. Science 1994;265:346-355
3. Sakamuro D, Sabbatini P, White E, Prendergast GC: The polyproline region of p53 is required to activate apoptosis but not growth arrest. Oncogene 1997;15:887-898
4. Hainaut P, Hollstein M: p53 And human cancer: The first ten thousand mutations. Adv Cancer Res 2000;77:81-137
5. Vogelstein B, Lane D, Levine AJ: Surfing the p53 network. Nature 2000;408:307-310
6. Darnton SJ: Demystified ... p53. J Clin Pathol 1998;51:248-253
7. Reich NC, Levine AJ: Growth regulation of a cellular tumor antigen, p53, in nontransformed cells. Nature 1984;308: 199-201
8. el-Deiry WS, Kern SE, Pietenpol JA, Kinzler KW, Vogelstein B: Definition of a consensus binding site for p53. Nat Genet 1992;1:45-49
9. Li FP, Fraumeni JF, Mulvihill JJ, Blattner WA, Dreyfus MG, Tucker MA, Miller RW: A cancer family syndrome in twenty-four kindreds. Cancer Res 1988;48:5358-5362
10. Levine AJ: Tumor suppressor genes. In The Molecular Basis of Cancer. Edited by J Mendelsohn, PM Howley, MA Israel, LA Liotta. Philadelphia, WB Saunders, 1995, pp 86-104
11. Iggo R, Gatter K, Bartek J: Increased expression of mutant forms of p53 oncogene in primary lung cancer. Lancet 1990; 1:675-677
12. Kern SE, Kinzler KW, Bruskin A, Jarosz D, Friedman P, Prives C, Vogelstein B: Identification of p53 as a sequence-specific DNA-binding protein. Science 1991;252:1708-1711
13. Linden MD, Nathanson SD, Zarbo RJ: Evaluation of anti-p53 antibody staining: Quality control and technical considerations. Appl Immunohistochem 1994;2:218-224
14. Linden MD, Nathanson SD, Zarbo RJ: Evaluation of anti-p53 antibody staining immunoreactivity in benign tumors and nonneoplastic tissues. Appl Immunohistochem 1995;3:232-238
15. Dalbagni G, Presti JC, Reuter VE, Zhang ZF, Sarkis AS, Fair WR, Cordon-Cardo C: Molecular genetic alterations of chromosome 17 and p53 nuclear overexpression in human bladder cancer. Diagn Mol Pathol 1993;2:4-13
16. Tashira H, Isacson C, Levine R: p53 Gene mutations are common in uterine serous carcinoma and occur early in their pathogenesis. Am J Pathol 1997;150:177-185
17. Martins ACP, Faria SM, Cologna AJ, Suaid HJ, Tucci S Jr: Immunoexpression of p53 protein and proliferating cell nuclear antigen in penile carcinoma. J Urol 2002;167:89-93
18. Berggren P, Steineck G, Adolfsson J, Hansson J, Jansson O, Larsson P, Sandstedt B, Wijkström H, Hemminki K: p53 Mutations in urinary bladder cancer. Br J Cancer 2001;84: 1505-1511
19. Esrig D, Spruck CH, Nichols PW, Chaiwun B, Steven K, Groshen S, Chen SC, Skinner DG, Jones PA, Cote RJ: p53 Nuclear protein accumulation correlates with mutations in the p53 gene, tumor grade, and stage in bladder cancer. Am J Pathol 1993;143:1389-1397
20. Spruck CH, Rideout WM, Olumi AF, Ohneseit PF, Yang AS, Tsai YC, Nichols PW, Horn T, Hermann GG, Steven K, Ross RK, Yu MC, Jones PA: Distinct pattern of p53 mutations in bladder cancer: Relationship to tobacco usage. Cancer Res 1993;53:1162-1166
21. Habuchi T, Takahashi R, Yamada H, Ogawa O, Kakehi Y, Ogura K: Influence of cigarrette smoking and schistosomiasis on p53 gene mutation in urothelial cancer. Cancer Res 1993;53:3795-3799
22. Miyamoto H, Kubota Y, Shuin T, Torigoe S, Hosaka M, Iwasaki Y, Danenberg K, Danenberg PV: Analyses of p53 gene mutation in primary bladder cancer. Oncol Res 1993;5: 245-249
23. Ejarque MJ: Molecular study of genetic markers in urinary bladder cancer. Doctoral thesis, Barcelona University, 2000
24. Oliner JD, Kindler KW, Meltzer PS, George DL, Vogelstein B: Amplification of a gene encoding a p53-associated protein in human sarcomas. Nature 1992;358:80-83
25. Schmitz-Drëger BJ, Goebell PJ, Heydthausen M: p53 Immunohistochemistry in bladder cancer: Combined analysis: A way to go? Urol Oncol 2000;5:204-210
26. Têtu B, Larue H, Fradet Y: p53 Expression in superficial bladder cancer. Urol Integr Invest 2001;6:48-56
27. Esrig D, Elmajian D, Groshen S, Freeman JA, Stein JP, Chen SC, Nichols PW, Skinner DG, Jones PA, Cote RJ: Accumulation of nuclear p53 and tumor progression in bladder cancer. N Engl J Med 1994;331:1259-1264
28. Schmitz-Dräger BJ, van Roeyen CRC, Grimm MO, Gerharz CD, Decken K, Schulz WA, Bültel, Makri D, Ebert T, Ackermann R: p53 Accumulation in precursor lesions and early stages of bladder cancer. World J Urol 1994;12:79-83
29. Tyrkus M, Powell I, Fakr W: Cytogenetic studies of carcinoma in situ of the bladder: Prognostic implications. J Urol 1992;148:44-46
30. McKenney JK, Desai S, Cohen C, Amin MB: Discriminatory immunohistochemical staining of urothelial carcinoma in situ and non-neoplastic urothelium: An analysis of cytokeratin 20, p53, and CD44 antigens. Am J Surg Pathol 2001;25: 1074-1078
31. Reznikoff CA, Sarkar S, Jülicher KP, Burger MS, Jairaj BS, Puthenveettil JA, Jarrard DF, Newton MA: Genetic alterations and biological pathways in human bladder cancer pathogenesis. Urol Oncol 2000;5:191-203
32. Jahnson S, Karlsson MG: Predictive value of p53 and pRB immunostaining in locally advanced bladder cancer treated with cystectomy. J Urol 1998;160:1291-1296
33. Osen I, Fossa SD, Majak B: Prognostic factors in muscle-invasive bladder cancer treated with radiotherapy: An immunohistochemical study. Br J Urol 1998;81:862-869
34. Peyromaure M, Weibing S, Sebe P, Verpillat P, Toublanc M, Dauge MC, Boccon-Gibod L, Ravery V: Prognostic value of p53 overexpression in T1G3 bladder tumors treated with bacillus Calmette-Guérin therapy. Urology 2002;59:409-413
35. Jung I, Messing E: Molecular mechanisms and pathways in bladder cancer development and progression. Cancer Control 2000;7:325-334
36. Zolota V, Tsamandas AC, Melachrinou M, Batistatou A, Scopa C: Expression of CD44 protein in renal cell carcinomas: Association with p53 expression. Urol Oncol 2002;7: 13-17
37. Kattar MM, Grignon DJ, Sarkar FH, Flaherty LE, Shimoyama RK, Tabaczka PM, Sakr WA, Crissman JD: p53 Gene expression in sarcomatoid renal cell carcinoma. J Urol Pathol 1996; 5:207-221
38. Gotoh A, Shirakawa T, Hanioka K, Fujisawa M, Gohji K, Okada H, Arakawa S, Kamidono S: Relation to pulmonary metastasis of alteration in p53 and proliferating cell nuclear antigen in renal cell carcinoma. J Urol Pathol 2000;13:73-83
39. Chi S, de Vere White RW, Meyers FJ, Siders DB, Lee F, Gumelock PH: p53 In prostate cancer: Frequently expressed transition mutations. J Natl Cancer Inst 1994;86:926-933
40. Tamboli P, Amin MB, Xu HJ, Linden MD: Immunohistochemical expression of retinoblastoma and p53 tumor suppressor genes in prostatic intraepithelial neoplasia: Comparison with prostatic adenocarcinoma and benign prostate. Mod Pathol 1998;11:247-252
41. Al-Maghrabi J, Vorobyova L, Chapman W, Jewett M, Zielenska M, Squire JA: p53 Alteration and chromosomal instability in prostatic high-grade intraepithelial neoplasia and concurrent carcinoma: Analysis by immunohistochemistry, interphase in situ hybridization, and sequencing of laser-captured microdissected specimens. Mod Pathol 2001;14:1252-1262
42. Downing SR, Jackson P, Russell PJ: Mutations within the tumour suppressor gene p53 are not confined to a late event in prostate cancer progression: A review of the evidence. Urol Oncol 2001;6:103-110
43. Cher ML, Bova GS, Moore DH, Small EJ, Carroll PR, Pin SS: Genetic alterations in untreated metastases and androgen-independent prostate cancer detected by comparative genomic hybridization and allelotyping. Cancer Res 1996;56: 3091-3102
44. Qian J, Hirasawa K, Bostwick DG, Bergstralh EJ, Slezak JM, Anderl KL, Borell TJ, Lieber MM, Jenkins RB: Loss of p53 and c-myc overrepresentation in stage T2-3N1-3M0 prostate cancer are potential markers for cancer progression. Mod Pathol 2002;15:35-44
45. Moul JW, Bettencourt MC, Sesterhenn IA, Mostofi FK, McLeod DG, Srivastaga E: Protein expression of p53, bcl-2 and Ki-67 (MIB-1) as prognostic biomarkers in patients with surgically treated clinically localized prostate cancer. Surgery 1996;120:159-167
46. Brewster SF, Oxley JD, Trivella M, Abbott CD, Gillatt DA: Preoperative p53, Bcl-2, CD44 and E. Cadherin immunohistochemistry as predictor of biochemical relapse after radical prostatectomy. J Urol 1999;162:2040-2045
47. Peng HQ, Hogg D, Malkin D, Bailey D, Gallie BL, Bulbul M: Mutations of the p53 gene do not occur in testis cancer. Cancer Res 1993;53:3574-3578
48. Hou J, Kallakury BVS, Bui HX, del Rosario AD, Fisher HAG, Ross JS: E-cadherin and p53 expression in pure testicular seminomas. J Urol Pathol 1996;5:109-118
49. Korman HJ, Schultz DS, Linden MD, Miles BJ, Peabody JO: Proliferating cell nuclear antigen and mutant p53 staining in testicular non-seminomatous germ cell tumors: A pilot study. 1994;2:327-336
50. Kersemaekers AMF, Mayer F, Molier M, van Weeren PC, Oosterhuis JW, Bokemeyer C, Looijenga LHJ: Role of p53 and MDM2 in treatment response of human germ cell tumors. J Clin Oncol 2002;20:1551-1561
51. Baltaci S, Orhan D, Türkölmez K, Yesilli C, Bedük Y, Tulunay O: P53, bcl2 and bax immunoreactivity as predictors of response and outcome after chemotherapy for metastatic germ cell testicular tumours. BJU Int 2001;87:661-666
52. Martins ACP, Faria SM, Cologna AJ, Suaid HJ, Tucci S Jr: Immunoexpression of p53 protein and proliferating cell nuclear antigen in penile carcinoma. J Urol 2002;167:89-93
53. Lam KY, Chan AC, Chan KW, Leung ML, Srivastava G: Expression of p53 and its relationship with human papillomavirus in penile carcinomas. Eur J Surg Oncol 1995;21:613-616
54. Levi JE, Rahal P, Sarkis AS, Villa L: Human papillomavirus DNA and p53 status in penile carcinomas. Int J Cancer 1998; 76:779-783
55. Hanahan D, Weinberg RA: The hallmarks of cancer. Cell 2000;100:57-70
56. Dameron KM, Volpert OV, Tainsky MA, Bouck N: Control of angiogenesis in fibroblasts by p53 regulation of trombospondin-1. Science 1994;265:1582-1584